切换至 "中华医学电子期刊资源库"

中华消化病与影像杂志(电子版) ›› 2026, Vol. 16 ›› Issue (03) : 193 -198. doi: 10.3877/cma.j.issn.2095-2015.2026.03.001

指南与共识

血管包裹肿瘤簇在肝细胞癌影像诊疗中的临床应用专家共识(2026年版)
中国研究型医院学会放射学专业委员会, 上海抗癌协会实体肿瘤聚焦诊疗专业委员会   
  1. 1. 海军军医大学第三附属医院影像医学科
    2. 复旦大学附属肿瘤医院介入治疗科
  • 收稿日期:2024-12-01 出版日期:2026-06-01

Expert consensus on the clinical application of vessels encapsulating tumor clusters in the imaging diagnosis and treatment of hepatocellular carcinoma (2026 edition)

Chinese Society of Research-oriented Hospitals Radiology Professional Committee, Shanghai Anti-Cancer Association Specialized Committee for Focus Diagnosis and Treatment of Solid Tumors   

  1. 1. Department of Radiology, Third Affiliated Hospital of Naval Medical University
    2. Interventional Therapy Department, Fudan University Affiliated Cancer Hospital
  • Received:2024-12-01 Published:2026-06-01
引用本文:

中国研究型医院学会放射学专业委员会, 上海抗癌协会实体肿瘤聚焦诊疗专业委员会. 血管包裹肿瘤簇在肝细胞癌影像诊疗中的临床应用专家共识(2026年版)[J/OL]. 中华消化病与影像杂志(电子版), 2026, 16(03): 193-198.

Chinese Society of Research-oriented Hospitals Radiology Professional Committee, Shanghai Anti-Cancer Association Specialized Committee for Focus Diagnosis and Treatment of Solid Tumors. Expert consensus on the clinical application of vessels encapsulating tumor clusters in the imaging diagnosis and treatment of hepatocellular carcinoma (2026 edition)[J/OL]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2026, 16(03): 193-198.

血管包裹肿瘤簇(VETC)是肿瘤独特的组织学血管模式,与新的转移机制相关。近年来,VETC在肝细胞癌(HCC)中发生率及其预后意义备受关注。现有研究表明,VETC是肝切除和肝移植术后复发和总生存率的独立预测因子,并逐渐成为HCC研究的热点。此外,VETC还可能作为预测靶向治疗、介入治疗及其联合方案疗效的生物标志物。然而,目前国际上对HCC中VETC报告和临床应用尚未形成统一标准。为促进VETC在HCC预后评估与治疗决策中的规范化、可操作性应用,中国研究型医院学会放射学专业委员会和上海抗癌协会实体肿瘤聚焦诊疗专业委员会组织国内影像学、肝胆外科、介入学、肿瘤学、病理学等诊治领域的相关专家,基于现有循证医学证据并结合临床实践,经过多轮讨论与反复修订,形成《血管包裹肿瘤簇在肝细胞癌诊断与治疗中的临床应用中国专家共识(2026年版)》,以供国内同行参考,并将随证据积累持续更新完善。

Vessels encapsulating tumor clusters (VETC) is a unique histological vascular pattern associated with a novel mechanism of metastasis. In recent years, the incidence of VETC in hepatocellular carcinoma (HCC) and its prognostic significance have garnered significant attention. Current studies indicate that VETC serves as an independent predictor of recurrence and overall survival following liver resection and transplantation, and has gradually become a research hotspot in HCC. Furthermore, VETC may also function as a biomarker for predicting the efficacy of targeted therapy, interventional therapy, and their combined regimens. However, internationally standardized criteria for reporting and the clinical application of VETC in HCC are yet to be established. To promote the standardized and practical application of VETC in the prognostic evaluation and therapeutic decision-making for HCC, this consensus is developed by organizing domestic experts from fields including radiology, hepatobiliary surgery, interventional medicine, oncology, and pathology. Based on current evidence-based medical data and combined with clinical practice, and through multiple rounds of discussion and revisions, the "Expert consensus on the clinical application of vessels encapsulating tumor clusters in the diagnosis and treatment of hepatocellular carcinoma (2026 edition)" is formulated. This consensus is intended as a reference for domestic colleagues and will be continuously updated and refined with the accumulation of new evidence.

[1]
Vogel A, Meyer T, Sapisochin G, et al. Hepatocellular carcinoma[J]. Lancet, 2022, 400(10360): 1345-1362.
[2]
Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024[J]. CA Cancer J Clin, 2024, 74(1): 12-49.
[3]
Lu L, Wei W, Huang C, et al. A new horizon in risk stratification of hepatocellular carcinoma by integrating vessels that encapsulate tumor clusters and microvascular invasion[J]. Hepatol Int, 2021, 15(3): 651-662.
[4]
Fang JH, Zhou HC, Zhang C, et al. A novel vascular pattern promotes metastasis of hepatocellular carcinoma in an epithelial-mesenchymal transition-independent manner[J]. Hepatol (baltim Md), 2015, 62(2): 452-465.
[5]
Mazzieri R, Pucci F, Moi D, et al. Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells[J]. Cancer Cell, 2011, 19(4): 512-526.
[6]
Saharinen P, Eklund L, Pulkki K, et al. VEGF and angiopoietin signaling in tumor angiogenesis and metastasis[J]. Trends Mol Med, 2011, 17(7): 347-362.
[7]
Hanley KL, Feng GS. A new VETC in hepatocellular carcinoma metastasis[J]. Hepatol(baltim Md), 2015, 62(2): 343-345.
[8]
Renne SL, Woo HY, Allegra S, et al. Vessels Encapsulating Tumor Clusters(VETC) Is a Powerful Predictor of Aggressive Hepatocellular Carcinoma[J]. Hepatology, 2020, 71(1): 183-195.
[9]
Lin C, He Y, Liu M, et al. Vessels That Encapsulate Tumor Clusters(VETC) Predict cTACE Response in Hepatocellular Carcinoma [J]. J Hepatocell Carcinoma, 2023, 10: 383-397.
[10]
Wang JH, Li XS, Tang HS, et al. Vessels that encapsulate tumor clusters(VETC) pattern predicts the efficacy of adjuvant TACE in hepatocellular carcinoma[J]. J Cancer Res Clin Oncol, 2023, 149(8): 4163-4172.
[11]
Fang JH, Zhou HC, Zhang C, et al. A novel vascular pattern promotes metastasis of hepatocellular carcinoma in an epithelial-mesenchymal transition-independent manner[J]. Hepatology, 2015, 62(2): 452-465.
[12]
Liu K, Dennis C, Prince DS, et al. Vessels that encapsulate tumour clusters vascular pattern in hepatocellular carcinoma[J]. JHEP Rep, 2023, 5(8): 100792.
[13]
Akiba J, Nakayama M, Sadashima E, et al. Prognostic impact of vessels encapsulating tumor clusters and macrotrabecular patterns in hepatocellular carcinoma[J]. Pathol Res Pract, 2022, 238: 154084.
[14]
Yu Y, Fan Y, Wang X, et al. Gd-EOB-DTPA-enhanced MRI radiomics to predict vessels encapsulating tumor clusters(VETC) and patient prognosis in hepatocellular carcinoma[J]. Eur Radiol, 2022, 32(2): 959-970.
[15]
Chen FM, Du M, Qi X, et al. Nomogram Estimating Vessels Encapsulating Tumor Clusters in Hepatocellular Carcinoma From Preoperative Gadoxetate Disodium-Enhanced MRI[J]. J Magn Reson Imaging, 2023, 57(6): 1893-1905.
[16]
Zhang P, Ono A, Fujii Y, et al. The presence of vessels encapsulating tumor clusters is associated with an immunosuppressive tumor microenvironment in hepatocellular carcinoma[J]. Int J Cancer, 2022, 151(12): 2278-2290.
[17]
Chen ZY, Guo ZX, Lu LH, et al. The predictive value of vessels encapsulating tumor clusters in treatment optimization for recurrent early-stage hepatocellular carcinoma[J]. Cancer Med, 2021, 10(16): 5466-5474.
[18]
Chu T, Zhao C, Zhang J, et al. Application of a Convolutional Neural Network for Multitask Learning to Simultaneously Predict Microvascular Invasion and Vessels that Encapsulate Tumor Clusters in Hepatocellular Carcinoma[J]. Ann Surg Oncol, 2022, 29(11): 6774-6783.
[19]
Guan R, Lin W, Zou J, et al. Development and Validation of a Novel Nomogram for Predicting Vessels that Encapsulate Tumor Cluster in Hepatocellular Carcinoma[J]. Cancer Control, 2022, 29: 10732748221102820.
[20]
Akiba J, Nakayama M, Sadashima E, et al. Prognostic impact of vessels encapsulating tumor clusters and macrotrabecular patterns in hepatocellular carcinoma[J]. Pathol Res Pract, 2022, 238: 154084.
[21]
Yu Y, Liang X, Hou G, et al. Spectral computed tomography parameters for predicting vessels encapsulating tumor clusters (VETC) pattern in hepatocellular carcinoma: a pilot study[J]. Quant Imaging Med Surg, 2025, 15(4): 3285-3297.
[22]
Renne SL, Woo HY, Allegra S, et al. Vessels encapsulating tumor clusters(VETC) is a powerful predictor of aggressive hepatocellular carcinoma[J]. Hepatol(baltim Md, ), 2020, 71(1): 183-195.
[23]
Sheng X, Ji Y, Ren GP, et al. A standardized pathological proposal for evaluating microvascular invasion of hepatocellular carcinoma: a multicenter study by LCPGC[J]. Hepatol Int, 2020, 14(6): 1034-1047.
[24]
丛文铭, 步宏, 陈杰, 等. 原发性肝癌规范化病理诊断指南(2015年版)[J]. 解放军医学杂志, 2015, 40(11): 865-872.
[25]
中国医师协会肝癌专业委员会. 肝细胞癌伴微血管侵犯诊断和治疗中国专家共识(2024版)[J/OL]. 中华普通外科学文献(电子版), 2024, 18(5): 313.
[26]
Ding T, Xu J, Zhang Y, et al. Endothelium-coated tumor clusters are associated with poor prognosis and micrometastasis of hepatocellular carcinoma after resection[J]. Cancer, 2011, 117(21): 4878-4889.
[27]
Wang M, Wang Y, Cao L, et al. LI-RADS CT and MRI major feature association with vessels encapsulating tumor clusters pattern and recurrence in hepatocellular carcinoma: a preliminary study[J]. J Gastrointest Surg: Off J Soc Surg Aliment Tract, 2025, 29(11): 102181.
[28]
Wei Y, Huang S, Huang L, et al. CT-based radiomics features combined with AFP for predicting vessels encapsulating tumor clusters and prognosis of hepatocellular carcinoma[J]. J Hepatocell Carcino, 2025, 12: 2069-2081.
[29]
Ding Q, Deng X, Huang J, et al. Application value of enhanced CT imaging features in predicting vessels encapsulating tumor clusters (VETC) positivity in hepatocellular carcinoma[J]. Curr Med Imaging, 2025, 21: e15734056361565.
[30]
Feng Z, Li H, Zhao H, et al. Preoperative CT for characterization of aggressive macrotrabecular-massive subtype and vessels that encapsulate tumor clusters pattern in hepatocellular carcinoma[J]. Radiology, 2021, 300(1): 219-229.
[31]
Pan J, Huang H, Zhang S, et al. Intraindividual comparison of CT and MRI for predicting vessels encapsulating tumor clusters in hepatocellular carcinoma[J]. Eur Radiol, 2025, 35(1): 61-72.
[32]
Liu Z, Mao Y, Liu L, et al. Preoperative CT features for characterization of vessels that encapsulate tumor clusters in hepatocellular carcinoma[J]. Eur J Radiol, 2024, 179: 111681.
[33]
Wang Y, Wang M, Cao L, et al. A nomogram for preoperative prediction of vessels encapsulating tumor clusters(VETC) pattern and prognosis of hepatocellular carcinoma[J]. Am J Surg, 2024, 234: 172-178.
[34]
Li C, Wen Y, Xie J, et al. Preoperative prediction of VETC in hepatocellular carcinoma using non-Gaussian diffusion-weighted imaging at high b values: a pilot study[J]. Front Oncol, 2023, 13: 1167209.
[35]
Fan Y, Yu Y, Hu M, et al. Imaging features based on Gd-EOB-DTPA-enhanced MRI for predicting vessels encapsulating tumor clusters(VETC) in patients with hepatocellular carcinoma[J]. Br J Radiol, 2021, 94(1119): 20200950.
[36]
Fan Y, Yu Y, Wang X, et al. Texture Analysis Based on Gd-EOB-DTPA-Enhanced MRI for Identifying Vessels Encapsulating Tumor Clusters(VETC)-Positive Hepatocellular Carcinoma[J]. J Hepatocell Carcinoma, 2021, 8: 349-359.
[37]
Dong X, Yang J, Zhang B, et al. Deep Learning Radiomics Model of Dynamic Contrast-Enhanced MRI for Evaluating Vessels Encapsulating Tumor Clusters and Prognosis in Hepatocellular Carcinoma[J]. J Magn Reson Imaging, 2024, 59(1): 108-119.
[38]
Che F, Gao F, Li Q, et al. Fractal analysis based on Gd-EOB-DTPA-enhanced MRI for prediction of vessels that encapsulate tumor clusters in patients with hepatocellular carcinoma[J]. Int J Surg(lond Engl), 2025, 111(7): 4389-4399.
[39]
杨建荣, 钟敬涛, 刘天奇, 等. 术前超声造影和术中快速冰冻病理切片诊断VETC癌巢型肝细胞癌的价值及患者手术方式选择研究[J]. 中国临床新医学, 2021, 14(3): 262-266.
[40]
蓝春勇, 凌冰, 郭文文, 等. VETC(+)肝癌内皮细胞中波形蛋白的表达及其与超声造影表现的关系[J]. 中华肿瘤杂志, 2018, 40(2): 105-109.
[41]
Xu W, Zhang H, Zhang R, et al. Deep learning model based on contrast-enhanced ultrasound for predicting vessels encapsulating tumor clusters in hepatocellular carcinoma[J]. Eur Radio, 2025, 35(2): 989-1000.
[42]
Xu W, Huang B, Zhang R, et al. Diagnostic and prognostic ability of contrast-enhanced unltrasound and biomarkers in hepatocellular carcinoma subtypes[J]. Ultrasound Med Biol, 2024, 50(4): 617-626.
[43]
Toshida K, Itoh S, Toshima T, et al. Clinical significance of mechanistic target of rapamycin expression in vessels that encapsulate tumor cluster-positive hepatocellular carcinoma patients who have undergone living donor liver transplantation[J]. Ann Gastroenterol Surg, 2023, 8(1): 163-171.
[44]
Schnitzbauer AA, Filmann N, Adam R, et al. mTOR inhibition is most beneficial after liver transplantation for hepatocellular carcinoma in patients with active tumors[J]. Ann Surg, 2020, 272(5): 855-862.
[45]
Chen ZY, Guo ZX, Lu LH, et al. The predictive value of vessels encapsulating tumor clusters in treatment optimization for recurrent early-stage hepatocellular carcinoma[J]. Cancer Med, 2021, 10(16): 5466-5474.
[46]
He X, Liu Y, Dai T, et al. Pathological study of the tumor microenvironment after neoadjuvant therapy in hepatocellular carcinoma: difference of TACE combined with antiangiogenics and immunotherapy[J]. Hepatol Commun, 2025, 9(9): e0787.
[47]
Fang JH, Xu L, Shang LR, et al. Vessels That Encapsulate Tumor Clusters(VETC) Pattern Is a Predictor of Sorafenib Benefit in Patients with Hepatocellular Carcinoma[J]. Hepatology, 2019, 70(3): 824-839.
[48]
Lyu N, Kong Y, Mu L, et al. Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma[J]. J Hepatol, 2018, 69(1): 60-69.
[49]
Lin W, Lu L, Zheng R, et al. Vessels encapsulating tumor clusters: a novel efficacy predictor of hepatic arterial infusion chemotherapy in unresectable hepatocellular carcinoma[J]. J Cancer Res Clin Oncol, 2023, 149(19): 17231-17239.
[50]
Nasarre P, Thomas M, Kruse K, et al. Host-derived angiopoietin-2 affects early stages of tumor development and vessel maturation but is dispensable for later stages of tumor growth[J]. Cancer Res, 2009, 69(4): 1324-1333.
[1] 中国临床肿瘤学会乳腺癌专家委员会, 中国医师协会肿瘤多学科诊疗专业委员会, 广东省药学会. 乳腺癌内分泌治疗超说明书用药专家共识[J/OL]. 中华乳腺病杂志(电子版), 2026, 20(02): 69-81.
[2] 国家传染病医学中心. 发热伴血小板减少综合征合并细菌/真菌感染诊治与防控专家共识[J/OL]. 中华实验和临床感染病杂志(电子版), 2026, 20(02): 65-75.
[3] 蔡轶伦, 陈燕, 董金玲. 人类Runt相关转录因子、E-钙黏蛋白和Ras相关区域家族1A基因甲基化对丙型肝炎病毒相关肝细胞癌的诊断价值[J/OL]. 中华实验和临床感染病杂志(电子版), 2026, 20(02): 106-113.
[4] 泌尿功能障碍预防和治疗专家组. 尿液菌群移植在部分女性泌尿系统疾病中的应用规范专家共识[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2026, 20(02): 127-133.
[5] 中国研究型医院学会微创外科学专业委员会, 中国研究型医院学会智能医学专业委员会. 肝切除日归手术多学科专家共识(2026版)[J/OL]. 中华腔镜外科杂志(电子版), 2026, 19(02): 65-76.
[6] 邓玉飞, 王志鑫, 娄珂, 张林轩, 马桂春, 港措. 影像组学在肝癌精准诊断、疗效评估及治疗方案决策优化中应用[J/OL]. 中华肝脏外科手术学电子杂志, 2026, 15(02): 172-180.
[7] 中国医师协会结直肠肿瘤专业委员会, 中国抗癌协会NOSES专业委员会, 中国NOSES联盟. 结肠镜辅助结肠肿瘤经自然腔道取标本手术专家共识及操作标准[J/OL]. 中华结直肠疾病电子杂志, 2026, 15(02): 104-114.
[8] 中国医师协会结直肠肿瘤专业委员会单孔腹腔镜学组. 单孔腹腔镜结直肠手术专家共识(2025版)[J/OL]. 中华结直肠疾病电子杂志, 2026, 15(02): 97-103.
[9] 陈小坤, 杜顺达. 影像组学在肝细胞癌中的应用进展及挑战[J/OL]. 中华消化病与影像杂志(电子版), 2026, 16(02): 97-100.
[10] 高增霞, 贺云飞, 赵娜. DCE-MRI联合Gd-EOB-DTPA MRI纹理特征对肝细胞癌经导管动脉化疗栓塞术后疗效的评估[J/OL]. 中华消化病与影像杂志(电子版), 2026, 16(02): 108-113.
[11] 陈秀梅, 谢曼英, 陈思涓, 钟旭辉, 潘巧, 温丽娟, 本共识编写小组. 晚期非小细胞肺癌患者免疫相关不良反应的护理专家共识[J/OL]. 中华临床医师杂志(电子版), 2026, 20(02): 77-89.
[12] 印于, 俞斌, 冯文聪, 杨俊, 倪才方, 朱晓黎, 李智, 李明明. 动脉化疗栓塞联合锥形束断层扫描引导乙醇注射治疗危险部位小肝癌的疗效与安全性[J/OL]. 中华介入放射学电子杂志, 2026, 14(02): 157-163.
[13] 阿旺晋美, 格桑罗布, 雷彦明, 次旦旺久. 高海拔地区肝癌栓塞化疗联合靶免短期疗效预测模型构建与验证[J/OL]. 中华介入放射学电子杂志, 2026, 14(02): 164-170.
[14] 董振楠, 管恒星, 丁伟, 王卫东, 张金星, 周春高, 祖庆泉, 施海彬. 动脉化疗栓塞与灌注化疗分别联合靶免治疗肝细胞癌伴门静脉癌栓的对照研究[J/OL]. 中华介入放射学电子杂志, 2026, 14(02): 177-183.
[15] 中华医学会检验医学分会分子诊断学组, 中华医学会检验医学分会临床免疫学组, 中国民族卫生协会流式细胞技术临床应用推广组. 医疗机构临床流式细胞实验室建设专家共识[J/OL]. 中华临床实验室管理电子杂志, 2026, 14(02): 89-103.
阅读次数
全文


摘要


AI


AI小编
你好!我是《中华医学电子期刊资源库》AI小编,有什么可以帮您的吗?